Harvard Business Review December 14, 2017
David Blumenthal, M.D.

The U.S. health care system is begging for disruption. It costs way too much ($3.3 trillion last year) and delivers too little value. Hundreds of millions of Germans, French, English, Scandinavians, Dutch, Danish, Swiss, Canadians, New Zealanders, and Australians get comparable or better health services for half of what we pay. For most Americans, care is not only expensive but is also fragmented, inconvenient, and physically inaccessible, especially to the sickest and frailest among us.

It should come as no surprise, then, that when titans of our private, for-profit health care sector — like Aetna, CVS, UnitedHealth Group (UHG), and DaVita — strike out in new directions, stakeholders react with fascination and excitement. Could this be it? Is free-market magic...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Health System / Hospital, Healthcare System, Mergers & Acquisitions / JV, Payer, Retail care
Boston Scientific to buy Intera Oncology, maker of liver cancer treatment
Halozyme abandons its €2bn pursuit of Evotec
M&A Cyber Success Depends on Communication, an Honest Evaluation of Each Side’s Strengths & Risks, and an Open Mind
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
Weekly HCRE Briefing: AdventHealth to Acquire Two CHS Hospitals in FL | Kaiser Acquiring ASCs and MOBs

Share This Article